ArticleThe Journal of clinical endocrinology and metabolism2025
Associations of AMH in Midreproductive Years with Bone Mineral Density and Turnover Markers in Midlife.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Anti-Müllerian Hormone Levels Are Associated With Skeletal Maturity in Adolescent Girls: A Longitudinal Study.Health science reports · 2025Article
- Oxidative Stress, Parity History, and Remnant Follicles in the Aged Ovary: Insights on Ovarian Cancer Risk and Protection.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
contextThe concentration of circulating anti-Müllerian hormone (AMH) predicts short-term (3-5 years) bone loss around menopause. Whether AMH during midreproductive years predicts bone health over a decade later is unknown.
objectiveTo study the association of AMH levels in midreproductive years with bone density and turnover biomarkers measured after ∼14 years of follow-up.
methodsWe assessed plasma AMH in 2003-2006 (mean 37.0 years, SD 5.1) among 450 parous women (71% White) in a US longitudinal cohort, and bone mineral density (BMD; spine, hip, and femoral neck, measured by dual-energy X-ray absorptiometry) in 2017-2021 (mean 51.0 years, SD 5.1). Secondary outcomes were plasma levels of procollagen type I N-propeptide (PINP) and type I collagen cross-linked C telopeptide (CTX-I).
resultsIn linear regression models adjusted for demographics and lifestyle, compared with women with AMH >3.5 ng/mL, those with AMH <1.0 ng/mL had lower BMD (g/cm2) at follow-up (beta [95% CI] spine: -.06 [-0.10, -0.02]; hip: -.05 [-0.08, -0.02]; femoral neck: -.03 [-0.06, 0.00]) and higher bone turnover markers (beta [95% CI] PINP: .36 SD [0.10, 0.63]; CTX-I: .34 SD [0.07, 0.60]). The association of AMH with spine BMD was more pronounced among postmenopausal women in contrast to associations with bone turnover markers, which were more pronounced among women who had not yet reached menopause. The associations between AMH and BMD were primarily mediated by menopausal status at follow-up.
conclusionLower AMH during midreproductive years is associated with lower BMD and higher bone turnover 14 years later. Ovarian reserve during midreproductive years may be a valuable predictor of long-term bone health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.